tiprankstipranks
Advertisement
Advertisement
Theravance Biopharma Shareholders Back Directors and Governance Plans
PremiumCompany AnnouncementsTheravance Biopharma Shareholders Back Directors and Governance Plans
16d ago
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
Premium
Ratings
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
1M ago
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
Premium
Ratings
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
2M ago
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
PremiumThe FlyTheravance Biopharma price target raised to $15 from $13 at TD Cowen
3M ago
Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
Premium
Ratings
Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance
3M ago
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
Premium
The Fly
Theravance Biopharma reports Q4 EPS $1.15, consensus $1.10
3M ago
Theravance Biopharma downgraded to Neutral from Buy at B. Riley
PremiumThe FlyTheravance Biopharma downgraded to Neutral from Buy at B. Riley
4M ago
Theravance Biopharma price target lowered to $21 from $40 at BTIG
Premium
The Fly
Theravance Biopharma price target lowered to $21 from $40 at BTIG
4M ago
Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
Premium
The Fly
Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100